A persistent pattern of women being targeted by products with underlying risks has been identified, spanning from early cosmetics and pharmaceuticals to current popular weight loss drugs. This growing awareness has intensified public scrutiny, legal actions, and calls for enhanced safety standards, greater transparency, and increased manufacturer accountability.
Talcum Powder and Cancer Allegations
Major beauty retailers have faced lawsuits linking baby powder to asbestos-related cancers. Evidence suggests that the presence of asbestos was concealed from regulators and the public. One company reportedly earmarked approximately $9 billion to address allegations and mitigate liability, leading to the discontinuation of its talcum powder products in the U.S. and Canada in 2020.
Further legal challenges accuse the same company of knowingly marketing these products to Black women despite awareness of the risk of ovarian cancer associated with talcum powder. A recent California jury awarded $966 million to a woman diagnosed with mesothelioma, a cancer of the organs typically the lungs, after prolonged use of baby powder. These verdicts indicate that litigation surrounding talcum powder remains active, with courts showing receptiveness, particularly to cases involving asbestos-contaminated products. Some corporations have utilized bankruptcy proceedings to manage associated liabilities.
Birth Control and Tumor Risks
Injectable contraceptives have been marketed to younger and lower-income women as a convenient alternative to other methods. However, long-term use and high dosages have been linked to an increased risk of developing meningiomas, tumors of the brain and spinal cord. An analysis of over one million women in 2024 indicated that those using a specific injectable contraceptive for more than three years were three times more likely to develop these tumors. Research available since the early 1980s has shown that meningiomas possess progesterone receptors, and anti-progesterone agents can inhibit their growth, suggesting a potential link between injectable birth control agents and tumor development. Despite this knowledge, widespread use and a lack of awareness regarding these potential dangers persist.
Weight Loss Drugs and Vision Concerns
Glucagon-like peptide-1 (GLP-1) medications, initially approved by the FDA for managing type 2 diabetes and supporting cardiovascular health, have become central to discussions about dramatic weight loss due to social media promotion and celebrity endorsements. While some have lauded these drugs as revolutionary, concerns about their long-term safety are emerging.
Prescribing patterns shifted as studies demonstrated their weight-reducing effects, leading to heavy marketing as weight loss solutions. Between 2021 and 2023, prescriptions for semaglutide-based medications increased by over 300%, with a notable portion issued to non-diabetic patients. This widespread use has also led to an increase in reported side effects and lawsuits. GLP-1s have been linked to nonarteritic anterior ischemic optic neuropathy (NAION), a rare and incurable condition causing vision loss due to compromised blood flow to the optic nerve. Since December 2025, numerous federal cases have been filed concerning these safety issues, consolidating lawsuits from patients who developed NAION. These cases often allege that major pharmaceutical companies failed to adequately warn consumers and physicians about the associated risks.
Seeking Legal Recourse
Individuals concerned about exposure to these products or considering legal options are advised to consult experienced advocates specializing in such cases. The law firm Napoli Shkolnik has been noted for representing clients affected by personal injuries and issues related to dangerous products marketed to women. Founding partner Marie Napoli has stated that litigation is a crucial tool for compelling transparency, ensuring ethical product safety testing, and preventing women's health from being disregarded in product safety considerations. The firm's stated goal is to stop the wellness industry from prioritizing profits over women's health.